Art. 30 Directive (EU) 2001/83

In forcesince 30 Apr 2004cited 21×
1.

If two or more applications submitted in accordance with Articles 8, 10, 10a, 10b, 10c and 11 have been made for marketing authorisation for a particular medicinal product, and if Member States have adopted divergent decisions concerning the authorisation of the medicinal product or its suspension or revocation, a Member State, the Commission or the applicant or the marketing authorisation holder may refer the matter to the Committee for Medicinal Products for Human Use, hereinafter referred to as ‘the Committee’, for the application of the procedure laid down in Articles 32, 33 and 34.

2.

In order to promote harmonisation of authorisations for medicinal products authorised in the Community, Member States shall, each year, forward to the coordination group a list of medicinal products for which a harmonised summary of product characteristics should be drawn up.

The coordination group shall lay down a list taking into account the proposals from all Member States and shall forward this list to the Commission.

The Commission or a Member State, in agreement with the Agency and taking into account the views of interested parties, may refer these products to the Committee in accordance with paragraph 1.

The 10 that are cited most themselves, of 21.

  • Directive (EU) 2004/27Lawamends

  • Gesetz über den Verkehr mit Arzneimitteln25b39Law

    … (5) Bei einer abweichenden Entscheidung bezüglich der Zulassung, ihrer Aussetzung oder Rücknahme finden die Artikel 30, 32, 33 und 34 der Richtlinie 2001/83/EG Anwendung. Im Falle einer Entscheidung nach Artikel 34 der Richtlinie …

  • Judgment of the Court (First Chamber) of 16 October 2008. The Queen, on the application of Synthon BV v Licensing Authority of the DepartmenDecision

    In the course of those proceedings, the H igh Court of Justice of England and Wales, Queen’s Bench Division (Administrative Court) decided to stay the proceedings and refer the following questions to the Court for a preliminary …

    16 Oct 2008 · 62006CJ0452

  • Judgment of the General Court (Seventh Chamber, Extended Composition) of 5 May 2021. Pharmaceutical Works Polpharma S.A. v European MedicineDecision

    Thus, according to Article 30(1) of Directive 2001/83, if two or more applications submitted in accordance with Articles 8, 10, 10a, 10b, 10c and 11 of that directive have been made for marketing authorisation for a particular medicinal …

    5 May 2021 · 62018TJ0611

  • Regulation (EU) 2024/568Law

    … de 153100 EUR s’applique à l’évaluation réalisée dans le cadre d’une procédure engagée au titre de l’article 30 de la directive 2001/83/CE. La rémunération s’élève à 8500 EUR pour le rapporteur et à 8500 EUR pour le …

  • Judgment of the Court of First Instance (Fifth Chamber) of 31 January 2006. Merck Sharp & Dohme Ltd and Others v Commission of the European Decision

    Chapter 4 (‘Mutual recognition of authorisations’) of Title III HUM (‘Placing on the market’) contains the following provisions: ‘Article 27 [corresponding to Article 8 of Directive 75/319, as amended]: In order to facilitate the …

    31 Jan 2006 · 62003TJ0273

  • Opinion of Advocate General Medina delivered on 6 October 2022. European Commission and Others v Pharmaceutical Works Polpharma S.A.Decision

    Article 30 of Directive 2001/83 states: ‘1. If two or more applications submitted in accordance with Articles 8, 10, 10a, 10b, 10c and 11 have been made for marketing authorisation for a particular medicinal product, and if Member States …

    6 Oct 2022 · 62021CC0438

  • Council Regulation (EC) No 1905/2005 of 14 November 2005 amending Regulation (EC) No 297…1Law

    … 2001/83/EC (Article 4) Referral fee A referral fee of EUR 58 000 shall apply where the procedures laid down in Article 30(1) and Article 31 of Directive 2001/83/EC are initiated by the applicant of a marketing authorisation or the holder …

  • Code de la santé publiquer5121-41-7Law

    … nécessaire de la mettre en conformité avec une décision de la Commission européenne saisie dans le cadre des articles 30, 31 et 36 de la directive 2001/83/ CE du 6 novembre 2001 instituant un code communautaire relatif aux médicaments …

  • Judgment of the Court (Fourth Chamber) of 16 March 2023. European Commission and Others v Pharmaceutical Works Polpharma S.A.Decision

    Article 30(1) of Directive 2001/83 provides: ‘If two or more applications submitted in accordance with Articles 8, 10, 10a, 10b, 10c and 11 have been made for marketing authorisation for a particular medicinal product, and if Member …

    16 Mar 2023 · 62021CJ0438